NCT04608045View on ClinicalTrials.gov

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 19, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

CPX-POM

CPX-POM

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Lead Sponsor

CicloMed LLC
All Listed Sponsors
lead

CicloMed LLC

INDUSTRY

NCT04608045 - Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter